Surgery Partners, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Surgery Partners, Inc. (NASDAQ: SGRY) operates as a leading healthcare services company focused on surgical facilities and ancillary services in the United States. The company owns and/or operates more than 180 surgical facilities nationwide, including ambulatory surgery centers and surgical hospitals offering outpatient procedures across specialties such as orthopedics, ophthalmology, general surgery, spine, and total joint replacement; it provides ancillary services through diagnostic laboratories, multi-specialty physician practices, optical laboratories, and group purchasing organizations for optical products; and delivers integrated anesthesia services supporting its surgical operations. Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners serves patients, physicians, and payors with cost-effective, high-quality care through its three primary segments: Surgical Facility Services, Ancillary Services, and Optical Services. In recent developments, the company acquired multiple San Jose-based ambulatory surgery centers including Montpelier Surgery Center and Advanced Surgery Center in 2025 to expand its California footprint; added controlling interests in eight surgical facilities and several physician practices in 2024 for $378.8 million while issuing $800 million in senior notes for refinancing and growth; opened eight de novo facilities in 2024 with 12 more in development for 2025 openings, many targeting orthopedics; recruited over 750 physicians in 2024 and 150 in Q1 2025, alongside deploying 14 surgical robots and anticipating over 230 new physicians; and expanded its board with a healthcare veteran in early 2025 while reaffirming full-year guidance exceeding $3.075 billion in revenue and $508 million in adjusted EBITDA.
Fast-paced Momentum Stock Surgery Partners (SGRY) Is Still Trading at a Bargain
Why Fast-paced Mover Surgery Partners (SGRY) Is a Great Choice for Value Investors
Wall Street Analysts See a 26.14% Upside in Surgery Partners (SGRY): Can the Stock Really Move This High?
Surgery Partners vs. Viemed Healthcare: Which Outpatient Care Stock Is a Better Buy in 2026?
Surgery Partners, Inc. (SGRY) Q1 2026 Earnings Call Transcript
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
AUNA vs. SGRY: Which Hospital Stock Looks More Attractive Now?
Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
Reviewing Progyny (NASDAQ:PGNY) & Surgery Partners (NASDAQ:SGRY)
SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES
Surgery Partners (NASDAQ:SGRY) Reaches New 52-Week Low – What’s Next?
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES
SGRY GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED -- LEVI & KORSINSKY, LLP INVESTIGATES
8 Knots Management LLC Takes Position in Surgery Partners, Inc. $SGRY
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES
Surgery Partners, Inc. (SGRY) Presents at Barclays 28th Annual Global Healthcare Conference Prepared Remarks Transcript